Baxter International Inc. (BAX)
NYSE: BAX · Real-Time Price · USD
17.30
-0.48 (-2.70%)
At close: May 15, 2026, 4:00 PM EDT
17.25
-0.05 (-0.29%)
Pre-market: May 18, 2026, 5:27 AM EDT

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Infusion Therapies Revenue
4.09B4.10B4.10B
Infusion Therapies Revenue Growth
-0.32%-0.05%3.61%
Advanced Surgery Revenue
1.23B1.20B1.10B
Advanced Surgery Revenue Growth
3.00%8.51%5.04%
Medical Products & Therapies Revenue
5.32B5.30B5.21B
Medical Products & Therapies Revenue Growth
0.43%1.77%3.91%
Care & Connectivity Solutions Revenue
1.92B1.91B1.81B
Care & Connectivity Solutions Revenue Growth
0.42%5.35%0.78%
Front Line Care Revenue
1.15B1.16B1.14B
Front Line Care Revenue Growth
-0.60%2.02%-6.26%
Healthcare Systems & Technologies Revenue
3.07B3.07B2.95B
Healthcare Systems & Technologies Revenue Growth
0.03%4.07%-2.06%
Injectables and Anesthesia Revenue
1.32B1.35B1.37B
Injectables and Anesthesia Revenue Growth
-2.51%-1.53%1.93%
Drug Compounding Revenue
1.22B1.14B1.04B
Drug Compounding Revenue Growth
6.49%9.92%15.08%
Pharmaceuticals Revenue
2.53B2.49B2.41B
Pharmaceuticals Revenue Growth
1.60%3.40%7.20%
Other Revenue (Post-Q2 2023 Reporting)
393.00M381.00M67.00M
Other Revenue (Post-Q2 2023 Reporting) Growth
3.15%468.66%-22.99%
Revenue (Total)
11.32B11.24B10.64B
Revenue (Total) Growth
0.68%5.72%2.66%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
6.07B6.12B5.85B
United States Revenue Growth
-0.90%4.65%0.83%
Emerging Markets Revenue
-1.39B1.35B
Emerging Markets Revenue Growth
-3.26%0.52%
Rest of World Revenue
-3.73B3.44B
Rest of World Revenue Growth
-8.50%6.87%
International Revenue
5.25B5.12B4.79B
International Revenue Growth
2.56%7.02%5.00%
Revenue (Other)
--5.12B-4.79B
Revenue (Total)
11.32B11.24B10.64B
Revenue (Total) Growth
0.68%5.72%2.66%

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Medical Products & Therapies Operating Income
912.00M970.00M950.00M
Medical Products & Therapies Operating Income Growth
-5.98%2.10%-2.26%
Healthcare Systems & Technologies Operating Income
414.00M441.00M468.00M
Healthcare Systems & Technologies Operating Income Growth
-6.12%-5.77%-3.11%
Pharmaceuticals Operating Income
205.00M222.00M313.00M
Pharmaceuticals Operating Income Growth
-7.66%-29.07%-21.95%
Other Operating Income
45.00M43.00M18.00M
Other Operating Income Growth
4.65%138.89%-
Operating Income (Total)
-300.00M-308.00M14.00M
Operating Income (Total) Growth
---98.02%
Updated Apr 30, 2026. Data Source: Fiscal.ai.